Key facts
- Thirty Madison’s last known valuation is $500.0M (Aug 2025).
- It has raised $248.9M across 3 recorded rounds; the latest was Later Stage VC ($112.0M) in Mar 2022.
- Notable investors include Alumni Ventures, Gaingels, Calm Ventures, Greycroft, Evolution VC Partners — 40 tracked in total.
- Thirty Madison has filed 3 Form Ds with the SEC since 2017, most recently Mar 2022 ($112.0M sold to 83 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 40 names
- ·Watchlist + deal alerts for Thirty Madison
Funding rounds
3 roundsAbout Thirty Madison
Operator of a human-first healthcare company intended to support the unique needs of the community with personalized treatments and care. The company builds condition-specific brands that provide end-to-end care for hair loss, a cure for migraine, a treatment for allergies, and a facet for skin conditions, enabling patients to get specialized healthcare brands that create exceptional outcomes for all.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2016
- Employees
- 700
- Website
- thirtymadison.com/
- Ownership
- Privately Held (backing)
Thirty Madison doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Thirty Madison shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Thirty Madison in its N-PORT filings yet. We sweep new filings monthly.